Seropositive juvenile rheumatoid arthritis: analysis of the spectrum of clinical manifestations and therapy according to a retrospective study

Seropositive juvenile rheumatoid arthritis (JRA) is the rarest subtype of juvenile idiopathic arthritis (JIA) that is the equivalent of RA in adults and is manifested mainly by a symmetric polyarticular lesion, rapid structural disease progression with the formation of intraarticular erosions, the presence of positive rheumatoid factor (RF), and/or anti-cyclic citrullinated peptide (CCP) antibodies.

Objective: to analyze demographic, clinical, and laboratory features of seropositive JRA and drug therapy according to a retrospective 10-year study.

Patients and methods. The retrospective study enrolled patients diagnosed with seropositive JRA confirmed according to the ILAR classification, who were treated at the Childhood Rheumatology Department, V.A. Nasonova Research Institute of Rheumatology, from 2010 to 2020. Demographic indicators, data from clinical, laboratory, and instrumental examinations, and performed therapy were assessed.

Results and discussion. The investigation enrolled 70 patients, amounting to 6.5% of the total number of patients with all clinical types of JIA. Among them, there was a great preponderance of girls (88.6%); the ratio of boys to girls was 1:7.8. The median age of onset of JRA was 12.2 [7.0; 14.0] years; the median duration of disease at diagnosis verification was 6 [4; 12] months; the median number of active joints at diagnosis of JRA was 16.5 [10.75; 23.25]; oligoarthritis was identified in 11.2% of patients at disease onset (within the first 6 months). During the first year of the disease, radiographic Stages II, III, and IV were defined in 42.9, 50, and 7.1%, respectively. Positive RF was found in 94.3% of patients; there was positivity for anti-CCP antibodies in 78.6%, a combination of positivity for RF and anti-CCP antibodies in 72.9%; only positive anti-CCR antibodies were seen in 5.7%. The median ESR at diagnosis verification was 29 [19.75; 44.5] mm/h; that of CRP was 15.0 [6.9; 34.4] mg/l. The extra-articular manifestations of the disease were found in 18 patients (25.7% of the total number of patients): fever in 5 (7.2%); lymphadenopathy in 17 (24.3%); lung damage in 3 (4.3%); rheumatoid nodules in 2 (2.9%); pericarditis in 1 (1.4%) patient, and uveitis in 1 (1.4%). Sjögren's syndrome was diagnosed in 25.7% of patients; autoimmune thyroiditis in 8.6%. A family history of autoimmune diseases was recorded in 22.8%. Nonsteroidal anti-inflammatory drugs and glucocorticoids were used in 97.1 and 48.6% of patients; respectively; the patients received synthetic disease-modifying antirheumatic drugs (sDMARDs): only methotrexate (MTX) [n=55 (78.6%)], sequentially 2 sDMARDs [n=10 (14.3%)], 3 sDMARDs [n=5 (7.1%)]; biological agents (BAs) [n=66 (94.2%)]. During the first year of the disease, Biological therapy was initiated because of the rapid progression of the erosive process in 78.6% of patients. 64.3% of children took one BA, 18.6 and 7.1% received two and three BAs, respectively. Abatacept (ABC) as the first BA was used most often (45.7%). The reasons for revision of therapy were its secondary inefficiency in most cases and serious adverse reactions in 4 patients (ABC- and infliximab-related infusion reactions in 2 cases and conversion of tubercular tests in 2). The differences in the anti-CCP antibody detection rate were statistically insignificant in the group that used only one BA effectively long and in the group that needed to switch to another BA. When choosing a BA, preference was given to tocilizumab or rituximab (RTM) in patients with seropositive JRA in the presence of systemic manifestations, and high clinical and laboratory activities and to RTM or ABC in those with detected Sjögren's syndrome.

Conclusion. Seropositive JRA is a rare subtype of JIA that has an initially unfavorable course. Most patients require early aggressive therapy, including MTX and a BA due to the rapid progression of erosive arthritis. The presence of systemic manifestations and/or Sjögren's syndrome plays a defining role in choosing a specific BA. The presence of anti-CCP antibodies does not affect the selection or change of a BA.

1. Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. Philadelphia: Elsiever Saunders; 2016. P. 223-7.

2. Alekseeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Voprosy sovremennoi pediatrii. 2015;14(1):78-94. (In Russ.).

3. Oliveira S, Ravelli A, Pistorio АМ, et al. Proxy-reported healthrelated quality of life of patients with juvenile rheumatoid arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007 Feb 15;57(1):35-43. doi: 10.1002/art.22473.

4. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-34. doi: 10.1002/acr.23870. Epub 2019 Apr 25.

5. Oliveira-Ramos F, Eusebio M, Martins FM, et al. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016 Sep 22; 2(2):e000304. doi: 10.1136/rmdopen-2016-000304. eCollection 2016.

6. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012 Jun;64(6):2012-21. doi: 10.1002/art.34343. Epub 2011 Dec 19.

7. Jia J, Li J, Yao X, et al. Genetic architecture study of rheumatoid arthritis and juvenile idiopathic arthritis. PeerJ. 2020 Jan 15;8:e8234. doi: 10.7717/peerj.8234. eCollection 2020.

8. Nasonov EL, Lila AM. Rheumatoid arthritis: achievements and unsolved problems. Terapevticheskii arkhiv. 2019;91(5):4-7. (In Russ.).

9. Mahmud SA, Binstadt BA. Autoantibodies in the Pathogenesis, Diagnosis, and Prognosis of Juvenile Idiopathic Arthritis. Front Immunol. 2019 Jan 14;9:3168. doi: 10.3389/fimmu.2018.03168. eCollection 2018.

10. Lipinska J, Lipinska S, Kasielski M, Smolewska E. Anti-MCV and anti-CCP antibodies-diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA). Clin Rheumatol. 2016 Nov;35(11): 2699-706. doi: 10.1007/s10067-016-3355-1. Epub 2016 Jul 25.

11. Harrold LR, Salman C, Shoor S, et al. Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996–2009. J Rheumatol. 2013 Jul;40(7):1218-25. doi: 10.3899/jrheum.120661. Epub 2013 Apr 15.

12. Berthold E, Mansson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019 Oct 28;21(1):218. doi: 10.1186/s13075-019-1994-8.

13. Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019 Feb;46(2):190-7. doi: 10.3899/jrheum.180168. Epub 2018 Oct 1.

14. Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide populationbased study. Rheumatology (Oxford). 2017 Jun 1;56(6):928-933. doi: 10.1093/rheumatology/kew500.

15. Van Rossum M, van Soesbergen R, de Kort S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol. 2003 Apr;30(4):825-8.

16. Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014 Aug;73(8):1487-94. doi: 10.1136/annrheumdis-2012-203160. Epub 2013 May 28.

17. Sparchez M, Miu N, Bolba C, et al. Evaluation of anti-cyclic citrullinated peptide antibodies may be beneficial in RF-negative juvenile idiopathic arthritis patients. Clin Rheumatol. 2016 Mar;35(3):601-7. doi: 10.1007/s10067-015-2971-5. Epub 2015 May 21.

18. Das S, Padhan P. An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother. Jul-Sep 2017;8(3):81-6. doi: 10.4103/jpp.JPP_194_16.

19. Athreya BH, Doughty RA, Bookspan M, et al. Pulmonary manifestations of juvenile rheumatoid arthritis: a report of eight cases and review. Clin Chest Med. 1980 Sep; 1(3):361-74.

20. Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015 Oct;74(10): 1854-60. doi: 10.1136/annrheumdis-2014-205372. Epub 2014 May 19.